A novel endpoint for a cancer drug’s accelerated approval is more likely to get the go ahead from the US Food and Drug Administration if the sponsor has a fully accrued post-marketing study underway at the time of application, Oncology Center of Excellence Deputy Director Paul Kluetz said.
Kluetz noted this is one way in which an Oncology Center of Excellence project can help “de-risk” aspects of a...







